Evolent Health (EVH) Tops Q2 EPS by 5c; offers guidance

Evolent Health (NYSE: EVH) reported Q2 EPS of $0.30, $0.05 better than the analyst estimate of $0.25. Revenue for the quarter came in at $647.1 million versus the consensus estimate of $636.46 million.

GUIDANCE:

Evolent Health sees Q3 2024 revenue of $615-635 million, versus the consensus of $644.2 million.

Evolent Health sees FY2024 revenue of $2.56-2.6 billion, versus the consensus of $2.577 billion.

For earnings history and earnings-related data on Evolent Health (EVH) click here.

You May Also Be Interested In

• Cerebras Systems (CBRS) Misses Q1 EPS, Revenues Beat
• MSCI upgrades Bulgaria to Frontier, flags Indonesia and Turkey risks
• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat